Clik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Hydroxychloroquine Sulfate...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the...
View ArticleClik here to view.
Otsuka Pharmaceutical to Acquire Visterra
TOKYO & WALTHAM, Mass. Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuant to which Otsuka will...
View ArticleClik here to view.
Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the randomized, Phase 3 TOURMALINE-MM3 study met its primary endpoint, demonstrating...
View ArticleClik here to view.
Medidata NEXT Seoul and Shanghai Events Host Industry Thought Leaders at the...
SHANGHAI This week, the Asia Pacific segment of Medidata’s (NASDAQ:MDSO) global NEXT series continues with customer events in Seoul and Shanghai. Sessions will explore trends in virtual trials,...
View ArticleClik here to view.
レスメドとベリリーが合弁企業を設立して数多くの睡眠時無呼吸症の未治療患者へのサービス提供に貢献へ
サンディエゴ & サウスサンフランシスコ （ビジネスワイヤ） — 睡眠時無呼吸症治療とコネクテッドヘルスソリューションの世界的リーダー企業であるレスメド（NYSE: RMD、ASX: RMD）とアルファベット傘下のベリリーは本日、新たな合弁企業の設立で合意したと発表しました。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：...
View ArticleClik here to view.
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its...
HAYWARD, Calif. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Taiho Pharmaceutical Co.,...
View ArticleClik here to view.
EUSA Pharma：NICE核准靶向癌症免疫治疗药物QARZIBA®▼ (dinutuximab beta)用于治疗高危神经母细胞瘤患儿
英格兰赫默尔亨普斯特德 (美国商业资讯) — EUSA Pharma今天迎来了国立卫生和医护示范研究院(NICE)的一项决定，推荐靶向抗癌免疫治疗药物QARZIBA® (dinutuximab beta)用于治疗英格兰和威尔士NHS内的高危神经母细胞瘤患儿i。高危神经母细胞瘤是一种侵犯型神经母细胞瘤，后者是儿童期最常见的起源于脑外的实体瘤ii。dinutuximab...
View ArticleClik here to view.
ResMed与Verily成立合资企业，帮助治疗数百万未获得治疗的睡眠呼吸暂停患者
圣迭戈和南旧金山 (美国商业资讯) — 睡眠呼吸暂停治疗和联网健康解决方案的全球领导者瑞思迈(ResMed, NYSE: RMD, ASX: RMD)与Alphabet旗下公司Verily今天宣布达成协议，双方将成立一家新的合资企业。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
維持療法としてのニンラーロ（イキサゾミブ）を検討する第3相試験は主要評価項目を達成し、移植後の多発性骨髄腫患者で無増悪生存期間の統計的に有意な改善を実証
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
NINLARO® (ixazomib)维持治疗3期试验达到主要终点，显示多发性骨髓瘤移植后患者的无进展生存延长有统计学意义
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，3期TOURMALINE-MM3随机研究达到主要终点，显示NINLARO®...
View ArticleClik here to view.
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with...
TOKYO & NEW YORK Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA)...
View ArticleClik here to view.
Dr. Reddy’s Laboratories announces its intent to appeal court decision in...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced its...
View ArticleClik here to view.
New Study Investigates the Utility of Masimo PVi® as Part of Goal-Directed...
IZMIT, Turkey Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Kocaeli University in Turkey compared the performance of conventional fluid...
View ArticleClik here to view.
EUSA Pharma：NICEが高リスク神経芽腫の小児患者の治療薬として分子標的がん免疫療法剤QARZIBA®▼（ジヌツキシマブベータ）を承認
英へメルヘムステッド （ビジネスワイヤ） — EUSA...
View ArticleClik here to view.
Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in...
SOUTH SAN FRANCISCO, Calif. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir...
View ArticleClik here to view.
新研究调查Masimo PVi®在结直肠手术患者目标指导补液管理中的功用
土耳其伊兹密特 Masimo (NASDAQ: MASI)今天发布了近期发表的一项研究结果，土耳其科喀艾里大学的研究人员比较了择期结直肠手术患者传统补液管理(CFM)与采用Masimo PVi®（脉搏灌注变异指数，采用SET®脉搏氧饱和度仪传感器进行无创连续测量）的目标指导补液管理(GDFM)的功效。比较要点是手术期间晶体补液量和血乳酸及血清肌酐水平1。...
View ArticleClik here to view.
大腸手術を受ける患者における目標指向型輸液管理の一環としてのMasimo PVi®の有用性を検討する新研究
トルコ・イズミット （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、最近公表されたトルコのコジャエリ大学の研究者らが最近公表した研究の知見について発表しました。本研究では、選択的大腸手術を受ける患者で、従来型輸液管理（CFM）と、Masimo...
View ArticleClik here to view.
Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases,...
View ArticleClik here to view.
FDA Clears First Nanotechnology Peek Devices for Spinal Intervertebral Fusion
NASHUA, N.H. Vallum Corporation, a medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market a polyetheretherketone (PEEK)...
View ArticleClik here to view.
Blade Therapeutics Announces Initiation of Phase 1 Study of Lead Calpain...
SOUTH SAN FRANCISCO, Calif. Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the initiation of a Phase 1 clinical trial for its lead compound,...
View Article